e-learning
resources
Vienna 2012
Tuesday, 04.09.2012
MDR- and XDR-TB: clinical and public health experiences
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The efficacy of a rifabutin-containing regimen for rifabutin-susceptible multidrug-resistant tuberculosis
K.W. Jo, W. Ji, J. Lyu, Y.J. Jung, S.D. Lee, W.S. Kim, D.S. Kim, T.S. Shim (Seoul, Republic Of Korea)
Source:
Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Session:
MDR- and XDR-TB: clinical and public health experiences
Session type:
Poster Discussion
Number:
3319
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K.W. Jo, W. Ji, J. Lyu, Y.J. Jung, S.D. Lee, W.S. Kim, D.S. Kim, T.S. Shim (Seoul, Republic Of Korea). The efficacy of a rifabutin-containing regimen for rifabutin-susceptible multidrug-resistant tuberculosis. Eur Respir J 2012; 40: Suppl. 56, 3319
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis
Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017
Year: 2017
The individual-tailored treatment regimens for multidrug-resistant tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J 2013; 42: 504-512
Year: 2013
Efficacy and tolerability of linezolid in multidrug-resistant tuberculosis (MDR/XDR-TB)
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008
Linezolid in multidrug-resistant tuberculosis treatment
Source: Eur Respir J 2004; 24: Suppl. 48, 485s
Year: 2004
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
Source: Eur Respir J 2016; 48: 582-585
Year: 2016
Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J, 53 (1) 1801154; 10.1183/13993003.01154-2018
Year: 2019
Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience
Source: Eur Respir J 2016; 47: 333-336
Year: 2016
A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 722s
Year: 2004
Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients
Source: Eur Respir J 2013; 42: 1614-1621
Year: 2013
Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J , 49 (3) 1601612; DOI: 10.1183/13993003.01612-2016
Year: 2017
Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India
Source: Eur Respir J 2012; 39: 956-962
Year: 2012
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM)
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009
A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis
Source: Eur Respir J, 55 (1) 1901181; 10.1183/13993003.01181-2019
Year: 2020
Efficacy of empiric chemotherapy regimen in patients with multidrug resistant (MDR) tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 656s
Year: 2004
What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis?
Source: Eur Respir J 2009; 34: 1492-1494
Year: 2009
Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis
Source: Eur Respir J 2016; 47: 1229-1234
Year: 2016
Management of multidrug-resistant tuberculosis and patients in retreatment
Source: Eur Respir J 2005; 25: 928-936
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept